Notably, orally active DPPIV inhibitors are increasingly used in new therapies for T2DM, and these drugs lead to an increase in the levels of the hormone GLP-1, which is involved in the stimulation of insulin secretion and the increase in insulin sensitivity in tissues [123,124,125]. Here, GLP1R is linked to type 2 diabetes mellitus.